Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,661 public trials 325 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Active, Not Recruiting

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 102 Scottsdale, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Local Institution - 107 Little Rock, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 162 locations
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Arkansas Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health Moores Cancer Center San Diego, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 106 locations
View Trial Details
Active, Not Recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

NCT06353022

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • CH de la Côte Basque Bayonne, France
  • CHU Caen Caen, France
  • CHRU DIjon Dijon, France
  • Chd Vendee La Roche-sur-Yon, France
View all 19 locations
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Son Llatzer Palma de Mallorca, Balearic Islands, Spain
  • Hospital Universitario Marqués de Valdecilla Santander, Cantabria, Spain
  • Hospital Universitario de Salamanca Salamanca, Castille and León, Spain
  • Complejo Universitario Hospitalario de Santiago Santiago de Compostela, Galicia, Spain
View Trial Details
Active, Not Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 0131 Los Angeles, California, United States
  • Local Institution - 0126 Orange, California, United States
  • Local Institution - 0113 Sacramento, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 101 locations
View Trial Details

Related conditions